Withings Unveils ‘Longevity Station’ Smart Scale

Withings has introduced its latest innovation in personal health monitoring, the Body Scan 2 smart scale, priced at $599.95. This advanced device shifts the focus beyond simple weight tracking to provide a comprehensive analysis of cardiovascular and metabolic health. Building on the foundation of its predecessor, the new model incorporates a sophisticated array of sensors designed to deliver a detailed, non-invasive health assessment right in the home.

The scale features eight electrodes integrated into its platform, complemented by an additional four electrodes housed within a retractable handle. This design mirrors the original Body Scan but enhances accuracy by capturing upper-body data, a significant improvement over typical smart scales that rely solely on foot electrodes and lower-body measurements. By incorporating upper-body data, the Body Scan lineup achieves greater precision in body composition analysis than most competitors.

A major upgrade in the Body Scan 2 is its expanded biomarker tracking. Alongside standard metrics like weight, heart rate, and body composition, the device now includes a 90-second “longevity assessment.” This evaluation covers over 60 biomarkers, organized into key categories: heart pumping performance and electrical activity, hypertension risk, artery health, cellular health and metabolic efficiency, and glycemic regulation. Antoine Joussain, Withings’ director of product management for devices, explains the vision behind this expansion: the goal is to integrate powerful, daily biomarkers into a routine scale interaction.

To prevent information overload, users receive a simplified Health Trajectory score, which visualizes their “healthspan”, an estimate of years of good health they can anticipate. This high-level indicator is designed for easy daily, weekly, or monthly tracking, while the app handles the interpretation of the dozens of underlying biomarkers. This concept of a consolidated health score isn’t entirely new; companies like Whoop and Oura have introduced similar aging and cardiovascular age metrics. However, Withings differentiates its approach by tracking metabolic health non-invasively, eliminating the need for blood tests.

The scale employs two novel, non-invasive methods: bioimpedance spectroscopy (BIS) and foot sweat analysis. BIS sends currents at varying frequencies to assess cell membrane function as an indicator of metabolic health. The foot sweat analysis involves stimulating the sweat glands in the feet with a minor, safe current and measuring their response. A healthy response suggests well-functioning glands, while a diminished one can correlate with conditions like poorly controlled diabetes. These non-invasive methods allow for more frequent and convenient tracking compared to traditional blood work, though they are intended as early warning systems, not diagnostic tools.

Joussain emphasizes the smart scale’s unique advantage as a familiar household device people already use regularly, making it an ideal platform for consolidated, long-term health monitoring. He acknowledges the emotional challenges scales can present, potentially triggering body image issues or disordered eating. In response, Withings includes an Eyes-Closed Mode that displays only emojis on the scale’s screen while recording all data in the accompanying app, aiming to reduce anxiety. The long-term ambition is to redefine the scale as a “longevity station” focused on overall wellness, not just weight.

Regulatory approval remains a consideration. Two features, hypertension risk notifications and the six-lead EKG for atrial fibrillation detection, will require FDA clearance. Withings has a mixed history with the FDA process; some devices faced lengthy reviews, while others launched as wellness products to bypass regulation. For the Body Scan 2, the company is pursuing a new certification strategy aimed at accelerating market entry without compromising scientific rigor. The device will also comply with GDPR, HIPAA, and include ISO privacy and security certifications. If plans proceed smoothly, the Body Scan 2 is expected to launch in the second quarter of 2026.

(Source: The Verge)